Veru reports results from its Phase 2b QUALITY, maintenance extension of study

Veru (VERU) announced positive topline efficacy and safety results from the maintenance extension portion of the Phase 2b QUALITY clinical study. The Phase 2b Maintenance Extension clinical trial demonstrated that in 12 weeks after stopping semaglutide, the placebo monotherapy group regained 43% of body weight that was previously lost during the Phase 2b QUALITY study, while enobosarm monotherapy reduced weight regain by 46% in the enobosarm 3mg group and completely prevented fat regain and preserved lean mass in both enobosarm dose groups compared to placebo after semaglutide discontinuation. Enobosarm treatment also led to up to 93% greater loss of fat mass and 100% preservation of lean mass compared to the placebo group at the end of the study. Enobosarm monotherapy maintained a positive safety profile, with essentially no gastrointestinal side effects observed during the maintenance period.